Global Neurostimulation Device Market (Size of $5,656.1 million in 2015) to Witness 12.9% CAGR During 2016 – 2022

  • Published: July 2016

The global neurostimulation device market generated $5,656.1 million revenue in 2015 and is expected to advance at a CAGR of 12.9% during the forecast period. The increasing aging population, surging incidence of neurological conditions and other chronic diseases, growing prevalence of chronic pain, and rising awareness about the overall mental health are some major factors supporting the prosperity of the market.

Insights into Market Segments

Based on application, the neurostimulation device market is categorized into pain management, Parkinson’s disease, neurologic urinary and fecal incontinence, epilepsy, hearing loss, gastroparesis, and depression. Among these, the pain management category is expected to lead the market throughout the period of analysis, in terms of size as well as growth.

Implantable/internal and external neurostimulation devices are the two types of products available in the neurostimulation device market. Of these, the implantable/internal category is expected to be the faster growing in the market in the forecast period.

Increasing Prevalence of Chronic Pain and Development of Advanced Devices to Drive the Growth of the Neurostimulation Device Market

The increasing prevalence of chronic pain is a major factor responsible for the growth of the neurostimulation device market. These devices play an important role in the management of pain, which may be associated with various medical conditions. The players in the market are investing heavily in the research and development (R&D) activities aimed at coming up with novel and advanced devices.

Besides, the increasing prevalence of neurological disorders is also driving the growth of the neurostimulation device market, as these devices provide considerable relief from the pain and discomfort caused due to these diseases.

Neurostimulation Device Market Competitiveness

Some of the key companies present in the global neurostimulation device market include Aleva Neurotherapeutics SA, St. Jude Medical Inc., Medtronic PLC, Boston Scientific Corporation, LivaNova PLC, Cochlear Ltd., Neuropace Inc., Neurosigma Inc., MED-EL GmbH, Synapse Biomedical Inc., Neuronetics Inc., NDI Medical LLC, EnteroMedics Inc., and ImThera Medical.


Market Segmentation by Type

  • Implantable/Internal Neurostimulation Device
  • Spinal cord stimulation (SCS)
  • Deep brain stimulation (DBS)
  • Sacral nerve stimulation (SNS)
  • Vagus nerve stimulation (VNS)
  • Cochlear implants (CI)
  • Gastric electric stimulation (GES)
  • External Neurostimulation Device
  • Transcutaneous electrical nerve stimulation (TENS)
  • Transcranial magnetic stimulation (TMS)

Market Segmentation by Application

  • Pain Management
  • Parkinson’s Disease
  • Neurologic Urinary and Fecal Incontinence
  • Epilepsy
  • Hearing Loss
  • Gastroparesis
  • Depression

Market Segmentation by Geography

North America Neurostimulation Device Market

  • By Type
  • By Application
  • By Country - U.S., Canada and Rest of North America

Europe Neurostimulation Device Market

  • By Type
  • By Application
  • By Country - U.K., Germany, France, and Rest of Europe

Asia Neurostimulation Device Market

  • By Type
  • By Application
  • By Country - Japan, China, India, and Rest of Asia

Rest of the World (RoW) Neurostimulation Device Market

  • By Type
  • By Application
  • By Country - Brazil, Australia and Rest of ROW